NEW YORK, Dec. 27, 2025, 11:25 a.m. ET — Market closed (weekend)
Merck & Co., Inc. (NYSE: MRK) heads into the final days of 2025 with investors weighing a steady holiday-week climb in the shares against a familiar set of longer-term questions: how fast Merck can broaden growth beyond Keytruda, how policy and pricing shifts may reshape demand, and what the next wave of pipeline milestones could mean for earnings power into 2026 and beyond.
With U.S. stock exchanges closed for the weekend, the next actionable moment for MRK traders will be Monday’s session, when liquidity returns and any weekend headlines can reprice the stock quickly at the open.
Where Merck stock stands right now
Merck shares ended Friday’s regular session at $106.78, and were last indicated around $106.96 in late after-hours trading, according to MarketWatch.
Friday’s session also reflected the thin trading common in a holiday-shortened week: MRK traded about 6.27 million shares, roughly below its recent average daily volume (about 13.87 million, per MarketWatch).
The main MRK headlines from the last 24–48 hours
Even with lighter news flow into the weekend, a few MRK-specific items circulated over the past two days that investors are actively parsing:
1) Merck highlighted as a “quality” large-cap in year-end market positioning
A Barron’s feature published Friday framed Merck as one of several “quality” stocks that screen as discounted versus broader-market valuations—an argument built around free cash flow resilience and the view that the market’s preference for lower-quality/speculative names is unlikely to persist. In that context, Merck’s pipeline and capital allocation strategy (including acquisitions aimed at offsetting eventual Keytruda pressure) were called out as key parts of the bull case. Barron’s
2) Short-interest data update drew attention
Benzinga reported within the last day that Merck’s short interest as a percentage of float rose versus the prior reporting period, citing exchange-reported data. The article pegged short interest at about 37.16 million shares and roughly 1.67% of float, with “days to cover” around 2.63 based on recent trading volumes. Benzinga
3) Institutional-positioning stories (13F-related) continued to roll
MarketBeat published multiple institution-focused items over the past day, including coverage of managers trimming MRK exposure based on reported holdings. These are not company fundamentals in themselves, but they can influence short-term sentiment—especially into year-end rebalancing.
Policy and pricing: the story that’s still shaping the MRK narrative
While not within the last 48 hours, the most consequential headline still echoing through MRK trading conversations is Merck’s December 19 announcement of an agreement with the U.S. government focused on expanding access and lowering costs.
In that release, CEO Robert M. Davis positioned the agreement as a step toward reducing pricing imbalances and improving affordability, saying the deal aims to help ensure Americans can access needed medicines “at lower costs.” Merck.com
The same announcement laid out several investor-relevant details, including:
- A plan to provide certain products via a direct-to-patient program, including JANUVIA, JANUMET, and JANUMET XR, described as priced at roughly 70% off list price for eligible patients.
- An intention to expand the program in the future to include enlicitide decanoate if approved.
- Reference to an understanding to delay Section 232 tariffs for three years, tied to U.S. reshoring/manufacturing investments.
For MRK stock, the market question is less about the headline and more about the downstream math: whether expanded affordability and direct channels support volume and durability, and how any margin tradeoffs compare with the strategic benefit of reduced policy uncertainty.
Pipeline catalysts investors keep circling
Merck’s valuation debate remains tightly linked to pipeline execution, especially as the market looks past Keytruda’s long runway and toward the late-decade patent landscape.
Key developments still in focus include:
- FDA “national priority” vouchers and fast-track dynamics: Reuters reported in December that the FDA granted national priority vouchers to Merck’s experimental cholesterol pill enlicitide and its cancer therapy sacituzumab tirumotecan (sac‑TMT)—part of a program designed to accelerate review timelines for select products. Reuters+1
- KEYTRUDA + Padcev in muscle-invasive bladder cancer (MIBC): Merck announced December 17 data indicating the KEYTRUDA-plus-Padcev regimen significantly improved key outcomes in cisplatin-eligible patients when used before and after surgery.
- WINREVAIR (sotatercept) regulatory momentum in Europe: Business Wire carried Merck’s update that an EMA committee (CHMP) issued a positive opinion for an expanded use of WINREVAIR in adults with pulmonary arterial hypertension.
These aren’t just “science” headlines for equity investors—they are the building blocks for a post-Keytruda earnings bridge. Each readout, filing, approval, label expansion, or commercial update tends to reframe the probability-weighted revenue curve the market assigns to Merck’s next generation of products.
Wall Street forecasts: targets, earnings timing, and what the Street is modeling
Price targets and consensus range
On Barron’s, MRK’s published analyst target range shows a high of $139, a low of $83, and an average near $110.52 (as displayed on the site’s research/ratings snapshot).
Yahoo Finance lists a 1-year target estimate around $110.04.
Next earnings date
Merck’s investor relations calendar lists the Q4 2025 earnings call on Feb. 3, 2026.
Nasdaq’s earnings page also shows an estimated earnings report date of 02/03/2026 (noting its estimate methodology).
EPS expectations into that print
Zacks’ earnings calendar page indicates an expectation of roughly $2.08 in earnings per share for the upcoming report.
Dividend
Yahoo Finance shows Merck’s forward dividend and yield at $3.40 annually and about 3.18%, with an ex-dividend date of Dec. 15, 2025.
What investors should know before the next session
With markets closed now, Monday’s open becomes a “reset point” where any incremental information—policy headlines, competitor data, sector rotations, or analyst notes—can matter more than usual. Here are the practical MRK-specific items to keep on the radar before the bell:
- Expect “catch-up” price discovery: MRK finished Friday near $106.78 and traded slightly higher after hours; Monday’s open will reflect any weekend macro or healthcare headlines that shift risk appetite. MarketWatch
- Watch volume and spreads early Monday: Friday’s volume was notably lighter than typical, which can sometimes exaggerate short-term moves; higher Monday liquidity can either confirm or fade late-week trends.
- Policy headlines can move large-cap pharma quickly: Merck’s recent U.S. affordability and direct-to-patient messaging remains a focal narrative into year-end and could be re-referenced in market commentary.
- Pipeline/oncology updates remain the core swing factor: Any fresh commentary related to enlicitide, sac‑TMT, KEYTRUDA combinations, or WINREVAIR can influence MRK’s multiple—because those programs anchor the market’s “beyond Keytruda” debate. Reuters+2Merck.com+2
- Analyst-target framing suggests limited “blue-sky” without catalysts: With the displayed average target near the low-$110s, big upside cases generally require either a pipeline win, a clearer post-Keytruda transition story, or a favorable policy backdrop. Barron’s+1
As trading returns Monday, MRK will likely continue to behave like what it is: a mega-cap defensive healthcare name whose near-term tape can be influenced by positioning and holiday liquidity—but whose longer-term direction still hinges on execution in oncology, cardiometabolic strategy, and the cadence of late-stage pipeline milestones.
